Virpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory Viruses
Nasal Powder Spray May Provide Barrier for Cell Transmission of Respiratory Infections
Virpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory Viruses
Nasal Powder Spray May Provide Barrier for Cell Transmission of Respiratory Infections